Cognigen Corporation, A Division Of Simulations Plus

Cognigen Corporation, A Division Of Simulations Plus company information, Employees & Contact Information

Advancing the Science and Engineering the Systems of Model-Based Drug Development Cognigen Corporation, a division of Simulations Plus provides strategic clinical pharmacology and pharmacometric consulting services, PK/PD model development, clinical trial simulations, exposure-response evaluations, and related data management services including analysis dataset creation and documentation. Cognigen’s multidisciplinary scientific teams reliably deliver high quality comprehensive technical reports synthesizing analysis findings to enable knowledge-based decision-making at critical regulatory and drug development milestones. Our PERSPECTIVE Hypertext Data Analysis Mapping software and Internet-based client collaboration strategy allows integrated project teams real-time collaborative review of results and ensures relevant actionable findings.

Company Details

Employees
41
Founded
-
Address
1780 Wehrle Drive,
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Buffalo, NY
Looking for a particular Cognigen Corporation, A Division Of Simulations Plus employee's phone or email?

Cognigen Corporation, A Division Of Simulations Plus Questions

News

Simulations Plus Announces Preliminary Fiscal Year 2025 Results and Fiscal Year 2026 Guidance - Business Wire

Simulations Plus Announces Preliminary Fiscal Year 2025 Results and Fiscal Year 2026 Guidance Business Wire

The Bottom Fishing Club - Simulations Plus: Huge Potential In AI Drug Discovery - Seeking Alpha

The Bottom Fishing Club - Simulations Plus: Huge Potential In AI Drug Discovery Seeking Alpha

Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024 - Yahoo Finance

Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024 Yahoo Finance

Simulations Plus and the Institute of Medical Biology of the Polish Academy of Sciences Partnership Announces Results in Validation of ADMET Predictor® Models with Enhanced AI Drug Design - Business Wire

Simulations Plus and the Institute of Medical Biology of the Polish Academy of Sciences Partnership Announces Results in Validation of ADMET Predictor® Models with Enhanced AI Drug Design Business Wire

Simulations Plus to Participate in the Citizens Medical Devices and Healthcare Services Forum - Lelezard

Simulations Plus to Participate in the Citizens Medical Devices and Healthcare Services Forum Lelezard

Simulations Plus Wins FDA Grant for Revolutionary Drug Delivery Modeling Technology - Stock Titan

Simulations Plus Wins FDA Grant for Revolutionary Drug Delivery Modeling Technology Stock Titan

Simulations Plus to Participate in Upcoming Investor Conferences - Business Wire

Simulations Plus to Participate in Upcoming Investor Conferences Business Wire

Simulations Plus Inc (SLP) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges - Yahoo Finance

Simulations Plus Inc (SLP) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges Yahoo Finance

Simulations Plus: Benefiting From FDA Modernization And AI (NASDAQ:SLP) - Seeking Alpha

Simulations Plus: Benefiting From FDA Modernization And AI (NASDAQ:SLP) Seeking Alpha

Simulations Plus Invests in Clinical Development Technology Company Nurocor - Business Wire

Simulations Plus Invests in Clinical Development Technology Company Nurocor Business Wire

Simulations Plus Announces Rescheduling of Third Quarter Fiscal 2025 Earnings Release and Conference Call - Business Wire

Simulations Plus Announces Rescheduling of Third Quarter Fiscal 2025 Earnings Release and Conference Call Business Wire

Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies - Business Wire

Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies Business Wire

Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue - Business Wire

Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue Business Wire

Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results - Business Wire

Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results Business Wire

Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements - Business Wire

Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements Business Wire

Simulations Plus Reports Fourth Quarter and Fiscal 2024 Financial Results - Business Wire

Simulations Plus Reports Fourth Quarter and Fiscal 2024 Financial Results Business Wire

Simulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions - Business Wire

Simulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions Business Wire

Simulations Plus Acquires Pro-ficiency, Creating One-of-a-Kind Platform Spanning the Drug Development Continuum - Business Wire

Simulations Plus Acquires Pro-ficiency, Creating One-of-a-Kind Platform Spanning the Drug Development Continuum Business Wire

Simulations Plus (SLP) Fell due to Concerns Over the Funding Environment - Yahoo Finance

Simulations Plus (SLP) Fell due to Concerns Over the Funding Environment Yahoo Finance

SIMULATIONS PLUS (SLP) ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire

SIMULATIONS PLUS (SLP) ALERT: Bragar Eagel & Squire, P.C. GlobeNewswire

Simulations Plus: Further Downside Is Likely (Rating Downgrade) - Seeking Alpha

Simulations Plus: Further Downside Is Likely (Rating Downgrade) Seeking Alpha

Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities - Business Wire

Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities Business Wire

Simulations Plus Earnings Call: Mixed Results Amid Growth and Challenges - TipRanks

Simulations Plus Earnings Call: Mixed Results Amid Growth and Challenges TipRanks

Simulations Plus Inc (SLP) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance

Simulations Plus Inc (SLP) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... Yahoo Finance

SLP SECURITIES NEWS: Simulations Plus, Inc. Faces a - GlobeNewswire

SLP SECURITIES NEWS: Simulations Plus, Inc. Faces a GlobeNewswire

Johnson Fistel Investigates Simulations Plus Following Reports of Financial and Internal Control Issues - GlobeNewswire

Johnson Fistel Investigates Simulations Plus Following Reports of Financial and Internal Control Issues GlobeNewswire

Simulations Plus Reports Q3 Revenue Growth Amidst Loss - TipRanks

Simulations Plus Reports Q3 Revenue Growth Amidst Loss TipRanks

Simulations Plus and the University of Bath Awarded New FDA Grant - The AI Journal

Simulations Plus and the University of Bath Awarded New FDA Grant The AI Journal

Simulations Plus, Inc. (NASDAQ:SLP) Q3 2025 Earnings Call Transcript - Insider Monkey

Simulations Plus, Inc. (NASDAQ:SLP) Q3 2025 Earnings Call Transcript Insider Monkey

Modeling and Simulation of Acetaminophen Pharmacokinetics and Hepatic Biomarkers After Overdoses of Extended-Release and Immediate-Release Formulations in Healthy Adults Using the Quantitative Systems Toxicology Software Platform DILIsym - Wiley

Modeling and Simulation of Acetaminophen Pharmacokinetics and Hepatic Biomarkers After Overdoses of Extended-Release and Immediate-Release Formulations in Healthy Adults Using the Quantitative Systems Toxicology Software Platform DILIsym Wiley

Earnings call transcript: Simulations Plus beats Q4 2024 earnings expectations - Investing.com

Earnings call transcript: Simulations Plus beats Q4 2024 earnings expectations Investing.com

KeyBanc downgrades Simulations Plus stock rating on biopharma challenges - Investing.com

KeyBanc downgrades Simulations Plus stock rating on biopharma challenges Investing.com

Simulations Plus, Inc. (NASDAQ:SLP) Q1 2024 Earnings Call Transcript - Yahoo Finance

Simulations Plus, Inc. (NASDAQ:SLP) Q1 2024 Earnings Call Transcript Yahoo Finance

SLP Investors Have Opportunity to Join Simulations Plus, Inc. Fraud Investigation with the Schall Law Firm - Business Wire

SLP Investors Have Opportunity to Join Simulations Plus, Inc. Fraud Investigation with the Schall Law Firm Business Wire

Simulations Plus Names Sharlene Evans to Board of Directors - Business Wire

Simulations Plus Names Sharlene Evans to Board of Directors Business Wire

Parameterization of Physiologically Based Biopharmaceutics Models: Workshop Summary Report - ACS Publications

Parameterization of Physiologically Based Biopharmaceutics Models: Workshop Summary Report ACS Publications

Simulations Plus Acquires Lixoft, Expanding Modeling Software Offerings and Broadening Presence in Europe - Business Wire

Simulations Plus Acquires Lixoft, Expanding Modeling Software Offerings and Broadening Presence in Europe Business Wire

Simulations Plus: A Pick-and-Shovel Niche to Play the Speculative Drug Discovery Space - Yahoo Finance

Simulations Plus: A Pick-and-Shovel Niche to Play the Speculative Drug Discovery Space Yahoo Finance

Top 10 Simulation Software Companies | A Complete Tech Interface - Market.us Scoop

Top 10 Simulation Software Companies | A Complete Tech Interface Market.us Scoop

pK50─A Rigorous Indicator of Individual Functional Group Acidity/Basicity in Multiprotic Compounds - ACS Publications

pK50─A Rigorous Indicator of Individual Functional Group Acidity/Basicity in Multiprotic Compounds ACS Publications

SLP Stock Price and Chart — NASDAQ:SLP - TradingView

SLP Stock Price and Chart — NASDAQ:SLP TradingView

Simulations Plus (SLP) Stock Price, News & Analysis - MarketBeat

Simulations Plus (SLP) Stock Price, News & Analysis MarketBeat

Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP - PR Newswire

Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP PR Newswire

Top Cognigen Corporation, A Division Of Simulations Plus Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant